TB-500 Results Timeline

The short answer: there isn’t a real timeline

If you search “TB-500 results timeline” you’ll find tidy week-by-week charts — reduced inflammation by week one, “noticeable” recovery by week three, structural repair by week six, and so on. They look authoritative. They aren’t.

No completed, published human study has ever measured how long the injected TB-500 fragment takes to produce any tissue-repair result. There is no human efficacy trial for tendons, muscle, or joints, and no published human pharmacokinetic study of the fragment at all. Every “by week X” milestone you see is reverse-engineered from animal experiments and from people’s own reports — neither of which can establish a reliable clock.

That doesn’t mean nothing is knowable about timing. It means the honest version of this page is about why the timeline is uncertain, what the real drivers of healing time are, and how to tell a genuine improvement from the natural course of an injury. That’s more useful than a fabricated calendar.

Note: This page treats timing as physiology, not as a protocol. It does not provide doses, frequencies, or a titration schedule. For how access works and why fixed internet protocols are risky, see the legality and reviews pages linked throughout.

Half-life is not “time to results”

The one timing fact that does circulate with some basis is the half-life. TB-500’s plasma half-life is generally described as a matter of hours, with rodent pharmacokinetic work reporting a peak within roughly half an hour to an hour of injection and elimination over a few hours. Vendors then layer on a “loading then maintenance” schedule, implying the peptide accumulates and works over weeks.

Here’s the catch, and it’s the same trap that applies to BPC-157: how long a peptide lingers in your blood tells you almost nothing about when you’d notice a result. Soft-tissue repair is slow biology — collagen remodeling, cell migration, angiogenesis — that unfolds over weeks regardless of how quickly the signaling molecule clears. A short half-life doesn’t mean “fast results,” and a longer apparent persistence doesn’t mean “faster healing.” The dosing calendar and the healing calendar are two different clocks.

So the “loading phase” doesn’t earn its implied promise. Front-loading injections is a convention borrowed from how some peptides are dosed; it isn’t a demonstrated way to make tendon or muscle heal sooner. The injury sets the pace.

The borrowed clock: a different molecule, a different tissue

This is the part unique to TB-500, and it’s where most timelines quietly cheat.

“TB-500” is a synthetic 17-amino-acid fragment (the actin-binding region, Ac-LKKTETQ) of a much larger natural protein, full-length thymosin beta-4 (Tβ4, 43 amino acids). They are not the same substance. And essentially all of the human research — the studies that would let anyone draw a real time-course — was done on full-length Tβ4, not on the fragment.

Those human studies were also measuring the wrong things for the uses TB-500 is marketed for. Full-length Tβ4 has been trialed as an eye-surface treatment (corneal and ocular-surface healing, measured over days to weeks), as a topical wound treatment for pressure and venous ulcers (wound closure over weeks), and in early cardiac work after heart attack. None of that is a tendon-recovery clock or a physique timeline. A recombinant Tβ4 has also gone through early-phase safety and pharmacokinetic testing in healthy volunteers — but again, that’s the parent protein, and the endpoints were safety and blood levels, not athletic recovery.

So when a chart implies “human data shows TB-500 repairs tissue by week six,” it is borrowing a clock from a different molecule that was timed for a different body part. Even the most legitimate-looking human numbers are twice removed from what the page claims to describe. A 2025 orthopaedic scoping review reinforced the gap: direct human evidence for the injected fragment in musculoskeletal repair is essentially absent.

The stack problem: whose timeline is it?

There’s a second reason TB-500 timelines can’t be trusted at face value: almost nobody uses TB-500 by itself. It is overwhelmingly run alongside BPC-157 — the so-called “Wolverine stack” — and alongside the rest, ice, physical therapy, and load management that any sensible person does after an injury.

That makes attribution impossible. If someone reports “I was back to training by week five on TB-500,” they were almost certainly also taking a second peptide, resting the injury, and rehabbing it — and injuries get better with time and rehab on their own. There is no way to know which input, if any, drove the timeline. A “TB-500 timeline” is, in practice, a two-peptide-plus-recovery timeline wearing one peptide’s name.

What was actually in the vial?

A final wrinkle compounds all of the above. Because there’s no legitimate, standardized pharmacy product, the TB-500 people inject comes from the gray market, where actual content, concentration, and purity vary widely from vial to vial. Some vials are underdosed or degraded; some may not be the labeled substance at all.

That means two people reporting two different timelines may not even be timing the same thing. One person’s “nothing happened for a month” and another’s “felt it in a week” could reflect different products as much as different bodies. When the input isn’t standardized, the output timeline can’t be either. (For how to read those self-reports critically, see the reviews page.)

What actually governs how fast you heal

Strip away the peptide and the real drivers of recovery time are well understood — and they have nothing to do with a dosing schedule:

• Tissue type and blood supply. Well-vascularized muscle tends to recover faster than poorly perfused tendon, ligament, or cartilage. A tendon simply takes longer to remodel than a muscle strain, peptide or not.
• Severity and chronicity. A minor acute tweak resolves in weeks; a degenerative, months-old tendinopathy is a different timescale entirely. The starting injury dominates the clock.
• Age and baseline health. Healing slows with age and is affected by sleep, nutrition, blood sugar, smoking, and circulation.
• What you do in parallel. Relative rest, progressive loading, and good rehab are the interventions with the strongest evidence for recovery timelines. They’re also the confounders most likely to be credited to a peptide.

If you want a realistic mental model: expect the timeline of your injury, managed well, and treat any peptide as an unproven add-on, not the thing setting the schedule.

A more honest way to think about timing

Instead of a results calendar, think in terms of a review window — a structure a clinician can help you set up:

1. Establish a baseline before changing anything: a graded test of the painful movement, range of motion, a return-to-activity benchmark, and imaging where it’s appropriate.
2. Hold the other variables steady so a change can be interpreted — don’t simultaneously overhaul training, start three new supplements, and change your sleep.
3. Pick a reassessment point in advance and judge against the objective markers, not against how you feel on a good day.

This won’t give you the satisfying “week three” milestone the marketing promises. But it’s the only approach that can distinguish a real effect from natural healing, rest, regression to the mean, and expectation — the four things that fake a timeline most convincingly.

Where the law stands in 2026 (briefly)

TB-500 is not an FDA-approved drug, and its status is genuinely unsettled. The wellness-peptide nominations including TB-500 were removed from the FDA’s Category 2 list, and TB-500 is on the agenda for the FDA’s compounding advisory committee (PCAC) meeting scheduled for late July 2026. Crucially, removal from Category 2 is not the same as Category 1, not authorization, and not FDA approval — as of mid-2026 there is no clean, licensed pharmacy route, and the committee’s recommendation will be advisory, with rulemaking still to follow. It also remains banned at all times in sport under WADA’s S2 category.

The reclassification deep-dive page walls off the blow-by-blow; the point for this page is simply that timing claims sit on top of a substance with no approved use and no standardized product behind it.

Bottom line

There is no validated TB-500 timeline. The half-life is short but irrelevant to when you’d see a result; the human time-courses people cite belong to a different molecule studied for a different tissue; the reported timelines are confounded by stacking, rest, rehab, and unverified product; and the real clock is your injury’s, not a peptide’s. If you’re set on evaluating it, do it against an objective baseline with a clinician and a pre-set review point — not against a chart from a vendor.